Clinical and Laboratory Characteristics and Mortality in Korean Patients with Systemic Sclerosis: A Nationwide Multicenter Retrospective Cohort Study

Ki Won Moon, Shin-Seok Lee, Yun Jong Lee, Jae-Bum Jun, Su-Jin Yoo, Ji Hyeon Ju, Sung Hae Chang, In Ah Choi, Tae Young Kang, Eun Bong Lee, and Seung-Geun Lee

ABSTRACT. **Objective.** We aimed to investigate demographic and clinical features and predictors of mortality in Korean patients with systemic sclerosis (SSc).

Methods. We performed a retrospective multicenter medical chart review in Korean patients diagnosed with SSc from 1986 to 2016 at 11 university hospitals representing each geographic area of Korea. SSc patients were defined according to the American College of Rheumatology preliminary classification criteria and subtyped as limited cutaneous (lcSSc) or diffuse cutaneous (dcSSc) SSc.

Results. We enrolled 751 patients (female, 86.7%; mean age at diagnosis, 48.9 yrs). The most common organ involvement was interstitial lung disease (52.7%), followed by gastroesophageal reflux disease (32.9%) and pulmonary arterial hypertension (13.6%). Patients with lcSSc were more common than those with dcSSc (64.8 vs 35.2%), whereas anti-Scl-70 and anticentromere antibody positivity were identified in 302 (42.5%) and 175 (25.5%) patients, respectively. In the 46 (6.1%) patients who developed a malignancy, lung cancer (23.9%) was the most common diagnosis, followed by gastric (13%) and breast cancer (13%). During the study period, 57 (7.6%) patients died, and the 5- and 10-year survival rates were 94% and 87%, respectively. Increased age at diagnosis, cardiovascular involvement, and anti-Scl-70 antibody positivity were significant predictors of death.

Conclusion. Clinical manifestations and survival rates in Korean SSc patients are similar to those of other populations. However, the prevalence of anti-Scl-70 antibody is higher in Korean SSc patients compared with whites, while the prevalence of anticentromere antibody is lower. (First Release July 15 2018; J Rheumatol 2018;45:1281–8; doi:10.3899/jrheum.171443)

Key Indexing Terms:
SYSTEMIC SCLEROSIS   REPUBLIC OF KOREA
EPIDEMIOLOGY   NEOPLASMS   MORTALITY

Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology characterized by obliterative vasculopathy and fibrosis of the skin and internal organs, with a wide spectrum of clinical and laboratory manifestations[1]. Serious

organ involvement, such as pulmonary arterial hypertension (PAH), can develop in patients with SSc, and clinical outcomes in SSc are extremely unpredictable because of its highly variable course. Thus, SSc has a poorer prognosis than other autoimmune diseases[2]. Cases of SSc are classified as limited cutaneous (lcSSc) or diffuse cutaneous (dcSSc) according to the extent of skin involvement and categorized by disease-specific autoantibodies including those directed against Scl-70 (topoisomerase I), centromere protein, and RNA polymerase III (ARA). Thus, the associations between clini-coserological characteristics, severity, and outcome in patients with SSc can give valuable insight into disease pathobiology.

Considerable ethnic and geographic variation in clinical and laboratory features, severity, and mortality have been observed in previous studies[3,4,5], suggesting a link between genetic and environmental factors and the etiology of SSc. Thus, investigating the distinctive manifestations and outcome of SSc in different ethnic and geographic groups is important, not only for a better understanding of the characteristics of SSc but also to improve medical care in specific populations. However, previous assessments of the clinical characteristics in patients with SSc have focused on white populations or Western countries[2,6,7,8,9,10] and few studies have been performed in Asian subjects, especially Koreans. To date, 2 studies have reported the clinical features of SSc in Korean patients in the Korean language[11,12], while 1 study detailed disease-related mortality[13]. However, these were small-scale, single-center studies, and a nationwide study is needed to accurately identify the clinical features and mortality in Korean patients. The purpose of this study was to investigate demographic, clinical, and laboratory features of SSc in Korean patients and identify independent predictors of mortality in this population.

MATERIALS AND METHODS

Study design and population. We performed a retrospective multicenter cohort study in Korean patients diagnosed with SSc from 1986 to 2016 at 11 university hospitals representing each geographic area of Korea (Figure 1). Patient lists were compared to remove redundant cases. Patients were diagnosed according to the American College of Rheumatology (ACR) preliminary classification criteria for SSc[14]. Disease subtype (lcSSc and dcSSc) was categorized according to LeRoy, *et al*[15]. All study subjects were ethnically Korean. Patients with sine scleroderma or other autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), dermatomyositis, and polymyositis were excluded. The institutional review boards of each hospital approved the study protocol and waived patient informed consent because of the retrospective study design (IRB no. KNUH-2017-03-009 in Kangwon National University Hospital, CNUN-2017-082 in Chonnam National University Hospital, B-1801/447-402 in Seoul National University Bundang Hospital, HYUH 2017-05-023 in Hanyang University Hospital, CNUH 2017-03-023 in Chungnam National University Hospital, KC16OIMI0119 in Catholic Medical Center, 2017-06-018 in Soonchunhyang University Cheonan Hospital, 2017-03-003 in Chungbuk National University Hospital, CR315051-002 in Human Research Yonsei University Wonju Severance Christian Hospital, 1702-072-831 in Seoul National University Hospital, and 1704-013-054 in the Research and ERB of the Pusan National University Hospital).

Assessments. The 11 hospitals used the same predefined protocol to evaluate demographic, clinical, and laboratory features. We recorded the following for each patient: sex, SSc subtype, age at diagnosis, age at onset of Raynaud phenomenon (RP) and SSc, observation period, body mass index (BMI), residence (urban vs rural), modified Rodnan skin score (mRSS) at first visit, organ involvement, pulmonary function test (PFT) results, systolic pulmonary arterial pressure (PAP) on echocardiography; autoantibody status [including antinuclear antibody (ANA), anti-Scl-70 antibody, anticentromere antibody (ACA), and ARA], cancer, and death. Onset of scleroderma was defined as the first non-RP manifestation. The observation period was defined as the duration between diagnosis and the last followup. BMI was determined as weight in kg divided by the square of height in meters (kg/m^2), and mRSS was measured by experienced rheumatologists at each hospital. Gastroesophageal reflux disease (GERD) was defined as the presence of symptoms such as heartburn, reflux, and dysphagia, and reflux esophagitis on gastroscopy, esophageal dysmotility on manometry, or esophageal dilatation on chest computed tomography (CT). Interstitial lung disease (ILD) was defined as the presence of bibasilar pulmonary fibrosis on chest radiography or high-resolution CT without evidence of another lung disease[16]. Cardiovascular involvement was defined as symptomatic congestive heart failure, pericarditis, or a major conduction disturbance[17]. PAH was defined as a systolic PAP > 40 mmHg on echocardiography or mean PAP > 25 mmHg on right-sided heart catheterization. PAH diagnosed without evidence of ILD was considered isolated PAH[18]. A renal crisis was defined as rapidly progressive renal insufficiency with malignant hypertension or microangiopathic hemolytic anemia[19]. PFT results included forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1-to-FVC ratio (FEV1/FVC), and DLCO. ANA was detected by indirect immuno-fluorescence on HEp-2 cells, and anti-Scl-70 antibody, ACA, and ARA were determined by Euroline SSc profile line immunoassay. We also recorded cancer occurrence, type, and death during the followup period. Experienced rheumatologists retrieved all data by medical chart review at each hospital.

Statistical analysis. Data were expressed as the mean ± SD or number (%), as appropriate. Group comparisons were performed for continuous variables using Student t test and for categorical variables using the chi-square test or Fisher's exact test, as appropriate. The 5- and 10-year survival rates were calculated by Kaplan-Meier survival analyses, and comparisons of survival distributions were analyzed using the log-rank test. We first selected the significant prognostic factors by univariate analysis and then calculated independent predictors of mortality using a multivariate Cox proportional hazards model with backward selection. P values < 0.05 were considered statistically significant. All calculation was performed using SPSS Statistics for Windows, Version 23.0 (IBM Corp.) and Stata, Version 11.1 for Windows (StataCorp LLC).

RESULTS

We enrolled 751 Korean patients with SSc. The majority of patients (86.7%) were female, and the female-to-male ratio was 6:1 (Table 1). Two hundred sixty-four patients (35.2%) had dcSSc and 487 patients (64.8%) had lcSSc. The mean (± SD) age at diagnosis was 48.9 (± 13.3) years, and the mean ages of RP and scleroderma onset were 44.5 (± 14.6) and 46 (± 14.2) years, respectively. The peak age at diagnosis was in the 50s whereas peak onset ages of RP and scleroderma were in the 40s (Supplementary Figure 1, available with the online version of this article). The mean BMI and mRSS were 22.3 (± 13.3) kg/m^2 and 8.4 (± 7.1), respectively, and 584 patients (77.8%) lived in an urban area. The most common organ involvement was ILD (52.7%) followed by GERD (32.9%), PAH (13.6%), cardiovascular involvement (11.2%), renal crisis (2.5%), and isolated PAH (1.7%). The mean FVC, DLCO, and systolic PAP were 78.4% (± 19.8), 65.5%

Figure 1. Geographic distribution of 11 Korean hospitals in the present study.

(± 21.8), and 32.5 (± 16.6) mmHg, respectively. ANA, anti-Scl-70, ACA, and ARA were positive in 715 (96.6%), 302 (42.5%), 175 (25.5%), and 90 (15.8%) patients, respectively. Most patients had a single SSc-specific antibody, but 61 patients with SSc had > 1 SSc-related autoantibody; 29 of 671 (4.3%) with anti-Scl-70 and ACA, 26 of 565 (4.6%) with anti-Scl-70 and ARA, and 7 of 564 (1.2%) with ACA and ARA. One patient with SSc had triple SSc-specific autoantibodies. During the study period, death and cancer occurred in 57 (7.6%) and 46 (6.1%) patients, respectively. The most common malignancy was lung cancer (23.9%), followed by cancer of the stomach (13%), breast (13%), thyroid (10.9%), cervix (8.7%), and lymphoma (6.5%), and others (Supple-

mentary Table 1, available with the online version of this article).

Table 2 shows the comparisons of clinical features in patients with dcSSc and lcSSc. Patients with dcSSc were significantly younger at the time of the diagnosis than those with lcSSc (47.1 ± 13.3 vs 49.9 ± 13.2 yrs, p = 0.006). The dcSSc type was also associated with an earlier onset of RP (42.4 ± 14.5 vs 45.6 ± 14.6 yrs, p = 0.008) and scleroderma (44 ± 14.3 vs 47.2 ± 14.1 yrs, p = 0.006) than the lcSSc type. Patients with dcSSc had a higher mRSS (13.2 ± 7.2 vs 4.3 ± 3.6, p < 0.001) and lower FVC (72.9 ± 20% vs 81.8 ± 19%, p < 0.001), FEV1 (77.8 ± 20.1% vs 86.5 ± 20.7%, p < 0.001), and DLCO (62.1 ± 22.1% vs 67.7 ± 21.3%, p = 0.004) than

Table 1. Clinical and laboratory characteristics of patients with systemic sclerosis (SSc) in Korea. Values are n (%) or mean ± SD.

Characteristics	Patients with SSc, n = 751
Female	651 (86.7)
dcSSc/lcSSc	264 (35.2)/487 (64.8)
Age at diagnosis, yrs	48.9 ± 13.3
Onset age of RP, yrs	44.5 ± 14.6
Onset age of scleroderma, yrs	46.0 ± 14.2
Observation period, yrs	6.4 ± 5.6
BMI, kg/m^2	22.3 ± 13.3
Residence in urban area	584 (77.8)
mRSS	8.4 ± 7.1
GERD	247 (32.9)
ILD	396 (52.7)
Cardiovascular involvement	84 (11.2)
PAH	102 (13.6)
Isolated PAH, %	13 (1.7)
Renal crisis	19 (2.5)
Cancer	46 (6.1)
Death	57 (7.6)
Pulmonary function test	
FVC, % predicted	78.4 ± 19.8
FEV1, % predicted	83.1 ± 20.9
FEV1/FVC, % predicted	107.2 ± 13.7
DLCO, % predicted	65.5 ± 21.8
Systolic PAP, mmHg	32.5 ± 16.6
ANA	715/740 (96.6)
Anti-Scl-70 antibody	302/710 (42.5)
ACA	175/686 (25.5)
ARA	90/571 (15.8)

dcSSc: diffuse cutaneous SSc; lcSSc: limited cutaneous SSc; RP: Raynaud phenomenon; BMI: body mass index; mRSS: modified Rodnan skin score; GERD: gastroesophageal reflux disease; ILD: interstitial lung disease; PAH: pulmonary arterial hypertension; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; PAP: pulmonary arterial pressure; ANA: antinuclear antibody; ACA: anticentromere antibody; ARA: anti-RNA polymerase III.

Table 2. Comparison of clinical features between patients with dcSSc and lcSSc. Values are n (%) or mean ± SD.

Characteristics	dcSSc, n = 264	lcSSc, n = 487	p
Female	222 (84.1)	429 (88.1)	0.143
BMI, kg/m^2	21.0 ± 3.4	23.1 ± 16.6	0.088
Age at diagnosis, yrs	47.1 ± 13.3	49.9 ± 13.2	0.006
Onset age of RP, yrs	42.4 ± 14.5	45.6 ± 14.6	0.008
Onset age of scleroderma, yrs	44 ± 14.3	47.2 ± 14.1	0.006
Observation period, yrs	7.2 ± 5.8	5.9 ± 5.4	0.004
Residence in urban area	222 (84.1)	362 (74.3)	0.002
mRSS	13.2 ± 7.2	4.3 ± 3.6	< 0.001
GERD	112 (42.4)	135 (27.7)	< 0.001
ILD	178 (67.4)	218 (44.8)	< 0.001
Cardiovascular involvement	45 (17)	39 (8)	< 0.001
PAH	42 (15.9)	60 (12.3)	0.129
Isolated PAH	2 (0.8)	11 (2.3)	0.155
Renal crisis	13 (4.9)	6 (1.2)	0.002
Cancer	14 (5.3)	32 (6.6)	0.528
Death	32 (12.1)	25 (5.1)	0.001
Pulmonary function test			
FVC, % predicted	72.9 ± 20	81.8 ± 19	< 0.001
FEV1, % predicted	77.8 ± 20.1	86.5 ± 20.7	< 0.001
FEV1/FVC, % predicted	108.2 ± 15.0	106.5 ± 12.7	0.15
DLCO, % predicted	62.1 ± 22.1	67.7 ± 21.3	0.004
Systolic PAP, mmHg	33.3 ± 17.2	32.0 ± 16.3	0.418
ANA	253/258 (98.1)	462/482 (95.9)	0.137
Anti-Scl-70 antibody	152/246 (61.8)	150/464 (32.3)	< 0.001
ACA	25/233 (10.7)	150/453 (33.1)	< 0.001
ARA	33/195 (16.9)	57/376 (15.2)	0.583

dcSSc: diffuse cutaneous systemic sclerosis; lcSSc: limited cutaneous SSc; BMI: body mass index; RP: Raynaud phenomenon; mRSS: modified Rodnan skin score; GERD: gastroesophageal reflux disease; ILD: interstitial lung disease; PAH: pulmonary arterial hypertension; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; PAP: pulmonary arterial pressure; ANA: antinuclear antibody; ACA: anticentromere antibody; ARA: anti-RNA polymerase III.

patients with lcSSc. These were more frequently observed in patients with dcSSc than in those with lcSSc: GERD (42.4% vs 27.7%, p < 0.001), ILD (67.4 vs. 44.8%, p < 0.001), cardiovascular involvement (17% vs. 8%, p < 0.001), renal crisis (4.9% vs 1.2%, p = 0.002), and death (12.1% vs 5.1%, p = 0.001). The frequency of PAH, isolated PAH, and cancer were not significantly different between the 2 groups. As expected, the patients with dcSSc had a significantly higher frequency of anti-Scl-70 antibody and a significantly lower frequency of ACA compared with those with lcSSc. The frequency of ARA positivity was not significantly different between the 2 groups.

We also compared disease presentations according to the presence of the anti-Scl-70 antibody (Supplementary Table 2, available with the online version of this article). Patients with the anti-Scl-70 antibody were diagnosed at a younger age (45.3 ± 13.9 vs 51.5 ± 12.2 yrs, p < 0.001) and had an earlier onset of RP (39.8 ± 15 vs 48 ± 13.6 years, p < 0.001) and scleroderma (41.5 ± 14.4 vs 49.2 ± 13.4 years, p < 0.001) than those without this finding. Further, anti-Scl-70-positive patients had a higher mRSS (10.2 ± 7.7 vs 6.6 ± 5.9,

p < 0.001), frequency of dcSSc (50.3 vs 20.3%, p < 0.001), ILD (74.1 vs 38.9%, p < 0.001), and incidence of death (11.6 vs 4.7%, p < 0.001) than anti-Scl-70-negative patients; however, the frequency of isolated PAH was lower in anti-Scl-70-positive patients (0.3 vs 2.7%, p = 0.017). Additionally, patients with the anti-Scl-70 antibody had worse pulmonary function than those without this finding.

In our Kaplan-Meier analysis, the cumulative 5- and 10-year survival rates in all patients with SSc were 94% (95% CI 91.4–95.9%) and 87% (95% CI 82.9–90.3%), respectively (Figure 2). In the log-rank analysis, the presence of cardiovascular complications (p < 0.001) and anti-Scl-70 antibody (p = 0.003) were associated with poor survival (Supplementary Figure 2, available with the online version of this article). The Cox proportional hazards models for survival are described in Table 3. In univariate analyses, these factors were associated with decreased survival: age at diagnosis ≥ 50 years, male sex, residence in a rural area, ILD, cardiovascular involvement, PAH, renal crisis, cancer, FVC < 70%, DLCO < 60%, and anti-Scl-70 antibody positivity. The multi-

Figure 2. Overall survival curve of Korean patients with systemic sclerosis.

variate Cox proportional hazards model adjusting for confounding factors revealed these independent risk factors for death in our patients with SSc: increased age at diagnosis (HR 3.85, 95% CI 1.04–14.21; p = 0.043 for those 50–59 yrs and HR 9.95, 95% CI 2.35–42.25; p = 0.002 for those ≥ 60 yrs), cardiovascular involvement (HR 6.89, 95% CI 3.21–14.78; p < 0.001), and the presence of anti-Scl-70 antibody (HR 2.8, 95% CI 1.24–6.35; p = 0.014).

Table 3. The univariate and multivariate Cox proportional hazards models for death of Korean patients with SSc.

Variables	Univariate Analysis		Multivariate Analysis[†]	
	HR (95% CI)	p	HR (95% CI)	p
Age at diagnosis, yrs				
< 40 (ref.)	1.00		1.00	
40–49	1.77 (0.75–4.19)	0.195	2.81 (0.73–10.82)	0.133
50–59	2.58 (1.15–5.78)	0.022	3.85 (1.04–14.21)	0.043
≥ 60 yrs	3.94 (1.70–9.12)	0.001	9.95 (2.35–42.25)	0.002
Male	2.2 (1.13–4.27)	0.02	–	–
Residence in rural area	2.09 (1.14–3.84)	0.017	2.25 (0.94–5.42)	0.07
ILD	2.45 (1.27–4.75)	0.008	–	–
Cardiovascular involvement	4.31 (2.52–7.36)	< 0.001	6.89 (3.21–14.78)	< 0.001
PAH	4.66 (2.57–8.44)	< 0.001	–	–
Renal crisis	4.47 (2.11–9.49)	< 0.001	–	–
Cancer	2.56 (1.25–5.23)	0.010	–	–
FVC < 70%	2.90 (1.66–5.08)	< 0.001	–	–
DLCO < 60%	2.42 (1.28–4.58)	0.007	–	–
Anti-Scl-70 antibody	2.29 (1.31–4.01)	0.004	2.8 (1.24–6.35)	0.014
dcSSc (ref. lcSSc)	1.6 (0.95–2.7)	0.078	–	–

[†] Backward elimination from the full model of age, sex, skin subset, anti-Scl-70, residence in rural area, cardiovascular involvement, PAH, ILD, renal crisis, cancer, FVC < 70%, and DLCO < 60%. SSc: systemic sclerosis; ILD: interstitial lung disease; PAH: pulmonary arterial hypertension; FVC: forced vital capacity; dcSSc: diffuse cutaneous SSc; lcSSc: limited cutaneous SSc.

DISCUSSION

We performed a retrospective, multicenter cohort study throughout Korea to evaluate the clinical and laboratory characteristics of patients with SSc and analyze the risk factors for mortality in this population. To our knowledge, this is the largest and most representative study of the clinical features and mortality in Korean patients with SSc to date.

Demographic, clinical, and laboratory characteristics in patients with SSc in other nations are summarized in Table 4. Similar to our results, most SSc patients were female, and the mean age of onset ranged from 42 to 47 years. The female-to-male ratio and the frequency of organ involvement including GERD, ILD, PAH, and renal crisis were largely similar in our Korean patients with SSc and those in other countries. Anti-Scl-70 and ACA tended to be associated with dcSSc and lcSSc, respectively, regardless of study origin. Notably, although the lcSSc-to-dcSSc ratio was comparable in different SSc populations worldwide, considerable geographic variation in the prevalence of SSc-associated autoantibodies was found between studies (Table 4). The frequency of the anti-Scl-70 antibody in patients with SSc in the United States, Japan, and most European countries except for France was < 30%, whereas the same prevalence in China and Korea was 59.9% and 42.5%, respectively. ACA positivity was found in nearly 40% of German, Spanish, Belgian, and Japanese patients with SSc. In contrast, the prevalence of this antibody was about 20% in studies of patients in Korea, France, the United States, and Brazil, and even lower in Chinese and Malaysian populations (13.1% and 9.7%, respectively). Thus, compared to patients with SSc in other nations, those in Korea demonstrated a distinctive distribution of SSc-specific autoantibodies and had a higher frequency of the anti-Scl-70 antibody. Ethnic variations in SSc-related autoantibodies have also been reported in previous studies; for example, African Americans with SSc had a higher rate of anti-Scl-70 antibody and lower frequency of ACA than white patients[20,21]. The evidence suggests that geographic and ethnic background may have a substantial effect on the occurrence of SSc-associated antibodies[22,23], and further research is needed to clarify the clinical relevance of the disparities in SSc-related autoantibody profiles associated with geographic areas. In addition, our study revealed that 61 Korean patients with SSc had > 1 SSc-related autoantibody, a somewhat unexpected finding because coexistence of SSc-specific autoantibodies in the same patients is uncommon[24,25]. Whether this is a specific characteristic of Korean SSc warrants further investigation.

As with other autoimmune disorders such as RA and SLE, investigators have suggested that a close association exists between SSc and an increased risk of cancer[26,27,28,29,30]. Although the underlying pathophysiology has not yet been established, tissue fibrosis, autoantibodies, chronic inflammation, and the use of immunosuppressants may contribute to the development and progression of malignancy in patients with SSc[28,31,32]. In particular, patients with SSc are known to have a higher risk for lung cancer and hematologic malignancies than the general population[26,27]. However, a relationship between SSc and other malignancies such as breast, cervical, thyroid, and skin cancer has also been reported, although conflicting data exist[27,28]. In our study, 46 patients (6.1%) were diagnosed with a malignancy during the followup period, and the most common diagnosis was lung

Table 4. Comparison of clinical characteristics in patients with SSc in other populations worldwide. Values are n (%) or mean ± SD unless otherwise specified.

Characteristics	France/USA[10]	Germany[6]	Spain[7]	Belgium[8]	Brazil[9]	Japan[37]	China[42]	Malaysia[43]
No. study subjects	127/247	1483	916	438	947	405	419	31
Female	105 (83) /183 (81)	1236 (83.4)	796 (86.9)	352 (80.4)	–	376 (92.8)	–	28 (90)
Age, yrs	48.4 ± 15.6/47.2 ± 13.7	55.7 ± 13.7	53.5 ± 14.2	55.4 ± 13.2	–	–	–	51.3 ± 12.8
Onset age, yrs	–	–	45.9 ± 15.6	–	42.6 ± 14.1	47 ± 0.7	–	42.6 ± 13.4
dcSSc	24 (19)/116 (47)	484 (32.7)	243 (26.5)	86 (19.6)	235 (24.8)	132 (32.6)	–	9 (29)
lcSSc	69 (54)/104 (42)	674 (45.5)	568 (61.8)	279 (63.7)	712 (75.2)	273 (67.4)	–	22 (71)
mRSS, mean ± SD or median (range)	–	9.2 ± 9.2	–	4 (0–40)	–	–	–	–
GERD	–	–	526 (57.4)	153 (35)	897 (94.7)	187 (46.2)	–	23 (74.2)
ILD	–	–	418 (45.6)	101 (23)	538 (56.8)	204 (50.4)	–	–
Pulmonary fibrosis	40 (36)/75 (34)	512 (34.5)	–	–	–	–	–	18 (58.1)
PAH	–	–	161 (15.6)	35 (8)	221 (23.3)	65 (16)	–	18 (58.1)
Isolated PAH	9 (10)/18 (19)	234 (15.8)	43 (4.7)	–	–	–	–	–
Renal crisis	2 (2)/23 (9)	–	24 (2.7)	16 (3.7)	25 (2.6)	13 (3.2)	–	–
ANA	125 (98.4)/245 (99.1)	1341 (90.4)	840 (92.2)	409 (95.6)	839 (88.6)	–	–	–
Anti-Scl-70 antibody	45 (35)/54 (22)	409 (27.6)	173 (19.0)	102 (23.9)	152 (16.1)	82 (23.3)	251 (59.9)	10 (32.2)
ACA	18 (23)/52 (21)	539 (36.4)	356 (39.1)	177 (41.3)	209 (22.1)	127 (36.1)	56 (13.4)	3 (9.7)
ARA	4 (5)/61 (25)	–	–	26 (6.1)	–	–	4 (1.3)	2 (6.5)

SSc: systemic sclerosis; dcSSc: diffuse cutaneous SSc; lcSSc: limited cutaneous SSc; mRSS: modified Rodnan skin score; GERD: gastroesophageal reflux disease; ILD: interstitial lung disease; PAH: pulmonary arterial hypertension; ANA: antinuclear antibody; ACA: anticentromere antibody; ARA: anti-RNA polymerase III.

cancer (23.9%), followed by gastric (13%) and breast cancer (13%). Our findings were similar to those of 2 previously published Korean studies by Chang, *et al* and Kang, *et al*[30,33]. In Korea, the most common malignancy is reportedly thyroid cancer, followed by stomach and colon cancer. Because lung cancer is only the fourth most common cancer[34], we hypothesize that patients with SSc in Korea may have a higher risk of this disease than the general population, similar to the risk found in other countries.

The overall survival rate in our Korean patients with SSc was 94% at 5 years and 87% at 10 years. The survival rate of patients with SSc has gradually improved over the last decades[35]. Steen and Medsger demonstrated that the 10-year survival rate had improved from 54% in the 1970s to 66% in the 1990s in their Pittsburgh cohort[36]. After 2000, the survival rate continued to rise. Hashimoto, *et al* analyzed 405 Japanese patients with SSc from 1973 to 2008 and found a 10-year survival rate of 88%[37]. Sampaio-Barros, *et al* reported 5- and 10-year survival rates of 90% and 84%, respectively, in their 10-year analysis of 947 Brazilian patients ending in 2010[9]. The improved survival is thought to result from earlier diagnosis and referral to specialized centers and therapeutic advances such as angiotensin-converting enzyme inhibitors for the treatment of renal crisis[3]. The survival rate in our cohort was higher than that in the study by Kang, *et al* (5-yr survival rate, 88.5%), which used national health insurance data (Health Insurance Review and Assessment Services; HIRA) to evaluate Korean patients with SSc[33]. However, the diagnostic accuracy in that study is questionable because in the HIRA system, the primary diagnosis is entered for reimbursement purposes and can be provided by any medical doctor, including nonrheumatologists. Thus, their cases require validation by experts to achieve diagnostic certainty[38,39]. On the other hand, all the patients we enrolled were diagnosed by experienced rheumatologists in tertiary hospitals according to the ACR preliminary classification criteria. Thus, we suggest that the SSc mortality rates we found are more precise than those reported by Kang, et al[33].

Our data revealed that increased age at diagnosis, cardiovascular involvement, and anti-Scl-70 antibody positivity were independent risk factors for mortality in Korean patients with SSc, consistent with the findings in previous reports[13,40,41]. As discussed, the prevalence of the anti-Scl-70 antibody varies according to geographic region and patient ethnicity. Thus, the significant association between the anti-Scl-70 antibody and a higher risk of death suggests the possibility of racial and geographic disparities in SSc-related mortality. Further studies are needed to evaluate this relationship. Additionally, Korean patients with SSc with cardiovascular involvement had about a 7-fold higher risk of death (HR = 6.89) than those without this complication. Thus, careful screening and appropriate management of cardiovascular disease in patients with SSc are crucial to improving clinical outcomes.

This study had several limitations. First, because of the

retrospective study design, there might be errors related to data collection such as missing values or misclassifications. To avoid this problem, experienced rheumatologists retrieved and thoroughly reviewed the medical records in our present study. Second, because patients with SSc sine scleroderma were not included, our data may not fully reflect the entire spectrum of SSc. Last, we did not obtain data regarding the causes of death in patients with SSc. These can be classified as SSc-related death or as related to other causes, and cardiopulmonary involvement, infection, and cancer were reported to be the major causes of death in patients with SSc in previous studies[9,37,40]. Thus, further studies are needed to determine the causes of death in Korean patients with SSc.

Our study presents the clinical and laboratory characteristics of SSc in a large representative Korean cohort. ILD was the most common internal organ comorbid disease, and lung cancer was the most common malignancy in this population. The overall survival rate in Koreans with SSc was similar to that in other populations, but increased age at diagnosis, cardiovascular involvement, and anti-Scl-70 antibody positivity were all associated with a poor prognosis. Notably, the frequency of SSc-specific autoantibody positivity varies according to nationality, and Korean patients with SSc had a higher prevalence of anti-Scl-70 antibody positivity than other populations, suggesting the potential role of ethnic and geographic factors in autoantibody production and the clinical SSc phenotype.

ONLINE SUPPLEMENT
Supplementary material accompanies the online version of this article.

REFERENCES
1. Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord 2017; 2:137-52.
2. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al; Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002;81:139-53.
3. Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010;9:A311-8.
4. Walker UA, Tyndall A, Czirjak L, Denton CP, Farge-Bancel D, Kowal-Bielecka O, et al; EUSTAR co-authors. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis 2009;68:856-62.
5. Proudman SM, Huq M, Stevens W, Wilson ME, Sahhar J, Baron M, et al. What have multicentre registries across the world taught us about the disease features of systemic sclerosis? J Scleroderma Relat Disord 2017;2:169-82.
6. Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, et al; Registry of the German Network for Systemic Scleroderma. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 2008;47:1185-92.
7. Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Espinosa-Garriga G, Ramos-Casals M, Campillo-Grau M, et al. Registry of the Spanish network for systemic sclerosis: clinical

pattern according to cutaneous subsets and immunological status. Semin Arthritis Rheum 2012;41:789-800.

8. Vanthuyne M, Smith V, De Langhe E, Van Praet J, Arat S, Depresseux G, et al. The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile. J Rheumatol 2012;39:2127-33.

9. Sampaio-Barros PD, Bortoluzzo AB, Marangoni RG, Rocha LF, Del Rio AP, Samara AM, et al. Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients. J Rheumatol 2012;39:1971-8.

10. Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007;34:104-9.

11. Kang SW, Lee YJ, Cha HS, Kim HA, Park MH, Oh MD, et al. Study on the clinical characteristics of systemic sclerosis. Korean J Med 1999;57:979-87.

12. Park SK, Kim TH, Jun JB, Jung SS, Bae SC, Kim TY, et al. The clinical features and autoantibody profile of progressive systemic sclerosis in Korea. J Korean Rheum Assoc 2001;8:243-52.

13. Kim J, Park SK, Moon KW, Lee EY, Lee YJ, Song YW, et al. The prognostic factors of systemic sclerosis for survival among Koreans. Clin Rheumatol 2010;29:297-302.

14. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.

15. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.

16. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65: 2737-47.

17. Jaeger VK, Wirz EG, Allanore Y, Rossbach P, Riemekasten G, Hachulla E, et al; EUSTAR co-authors. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One 2016;11:e0163894.

18. Simeon CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology 2003;42:71-5.

19. Steen VD, Medsger TA Jr., Osial TA Jr, Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984;76:779-86.

20. Krzyszczak ME, Li Y, Ross SJ, Ceribelli A, Chan EK, Bubb MR, et al. Gender and ethnicity differences in the prevalence of scleroderma- related autoantibodies. Clin Rheumatol 2011;30:1333-9.

21. Nandiwada SL, Peterson LK, Mayes MD, Jaskowski TD, Malmberg E, Assassi S, et al. Ethnic differences in autoantibody diversity and hierarchy: more clues from a US cohort of patients with systemic sclerosis. J Rheumatol 2016;43:1816-24.

22. Carmona FD, Gutala R, Simeon CP, Carreira P, Ortego-Centeno N, Vicente-Rabaneda E, et al; Spanish Scleroderma Group. Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. Ann Rheum Dis 2012;71:114-9.

23. Ochoa E, Martin JE, Assasi S, Beretta L, Carreira P, Guillen A, et al; Spanish Scleroderma Group. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. Clin Exp Rheumatol 2015;4 Suppl 91:S31-5.

24. Spencer-Green G, Alter D, Welch HG. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med 1997;103:242-8.

25. Denton CP, Khanna D. Systemic sclerosis. Lancet 2017;390:1685-99.

26. Olesen AB, Svaerke C, Farkas DK, Sorensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010;163:800-6.

27. Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, et al. Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology 2013;52:143-54.

28. Zeineddine N, Khoury LE, Mosak J. Systemic sclerosis and malignancy: a review of current data. J Clin Med Res 2016;8:625-32.

29. Park JK, Yang JA, Ahn EY, Chang SH, Song YW, Curtis JR, et al. Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis. BMC Cancer 2016;16:381.

30. Chang SH, Park JK, Lee YJ, Yang JA, Lee EY, Song YW, et al. Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study. Arthritis Res Ther 2014;16:428.

31. Bernal-Bello D, de Tena JG, Guillen-Del Castillo A, Selva-O'Callaghan A, Callejas-Moraga EL, Marin-Sanchez AM, et al. Novel risk factors related to cancer in scleroderma. Autoimmun Rev 2017;16:461-8.

32. Shah AA, Casciola-Rosen L. Mechanistic and clinical insights at the scleroderma-cancer interface. J Scleroderma Relat Disord 2017;2:153-9.

33. Kang GW, Jung KH, Lee YS, Kim HJ, Yoon DY, Lee SH, et al. Incidence, prevalence, mortality and causes of death in systemic sclerosis in Korea: a nationwide population-based study. Br J Dermatol 2018; 178:e37-9.

34. Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH; Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat 2017;49:292-305.

35. Rubio-Rivas M, Simeon-Aznar CP, Velasco C, Mari-Alfonso B, Espinosa G, Corbella X, et al; RESCLE investigators, Autoimmune Diseases Study Group (GEAS). Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE). Clin Exp Rheumatol 2017;35 Suppl 106:40-7.

36. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.

37. Hashimoto A, Tejima S, Tono T, Suzuki M, Tanaka S, Matsui T, et al. Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol 2011;38:1931-9.

38. Park SJ, Kim HJ, Park H, Hann HJ, Kim KH, Han S, et al. Incidence, prevalence, mortality and causes of death in Takayasu Arteritis in Korea - a nationwide, population-based study. Int J Cardiol 2017;235:100-4.

39. Yoon HJ, Choi HY, Kim YK, Song YJ, Ki M. Prevalence of fungal infections using National Health Insurance data from 2009-2013, South Korea. Epidemiol Health 2014;36:e2014017.

40. Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al; EUSTAR group. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017;76:1897-905.

41. Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Espinosa-Garriga G, Campillo-Grau M, Ramos-Casals M, et al; Spanish Scleroderma Study Group (SSSG); Autoimmune Diseases Study Group (GEAS); Spanish Society of Internal Medicine (SEMI). Registry of the Spanish Network for systemic sclerosis: survival, prognostic factors, and causes of death. Medicine 2015;94:e1728.

42. Wang J, Assassi S, Guo G, Tu W, Wu W, Yang L, et al. Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin Rheumatol 2013;32:617-21.

43. Sujau I, Ng CT, Sthaneshwar P, Sockalingam S, Cheah TE, Yahya F, et al. Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort. Int J Rheum Dis 2015;18:459-65.